Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial

BACKGROUND: Alveolar soft-part sarcoma (ASPS) is a rare soft-tissue sarcoma that is unresponsive to chemotherapy. Cediranib, a tyrosine-kinase inhibitor, has shown substantial activity in ASPS in non-randomised studies. The Cediranib in Alveolar Soft Part Sarcoma (CASPS) study was designed to discri...

Descripción completa

Detalles Bibliográficos
Autores principales: Judson, Ian, Morden, James P, Kilburn, Lucy, Leahy, Michael, Benson, Charlotte, Bhadri, Vivek, Campbell-Hewson, Quentin, Cubedo, Ricardo, Dangoor, Adam, Fox, Lisa, Hennig, Ivo, Jarman, Katy, Joubert, Warren, Kernaghan, Sarah, López Pousa, Antonio, McNeil, Catriona, Seddon, Beatrice, Snowdon, Claire, Tattersall, Martin, Toms, Christy, Martinez Trufero, Javier, Bliss, Judith M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lancet Pub. Group 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6602919/
https://www.ncbi.nlm.nih.gov/pubmed/31160249
http://dx.doi.org/10.1016/S1470-2045(19)30215-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6602919/
https://www.ncbi.nlm.nih.gov/pubmed/31160249
http://dx.doi.org/10.1016/S1470-2045(19)30215-3

Ejemplares similares